Previous studies have shown that basal-type and post-EMT breast cancer cell lines are particularly sensitive to dasatinib, with elevated expression of genes such as moesin (MSN), caveolin-1 (CAV1), and yes-associated protein-1 (YAP1), which are associated with the SRC signaling pathway [59]. This evidence concerns the gene CAV1 and breast carcinoma.